Paul Lisenby, CEO of XTend Medical, said: “This agreement will deliver to AmeriChoice a comprehensive solution that will allow their diabetic patients to be remotely monitored and communicate results in order to effectively assist patients in managing their diabetes.
“This clearly distances XTend Medical from our competition. With this agreement in place, XTend Medical is in a very advantageous position in the marketplace.”